Cynthia Pussinen’s expertise spans the drug development continuum from research through commercialization. For the past 30 years, she has led the development, licensure, commercialization and/or subsequent delivery to patients, of more than 15 new medical therapies for patients globally, across various therapeutic areas and modalities. Prior to joining Sernova as CEO, Cynthia was the Chief Technical Officer for Spark Therapeutics, Inc., a fully integrated, commercial gene therapy company, and a member of the Roche Group. Prior to joining Spark in 2021, Cynthia's leadership roles include 6 years with Ipsen Biomeasure and Ipsen Biosciences, U.S. R&D focused subsidiaries of Ipsen, where she served as President and CEO. She was also the Executive Vice President, Technical Development, Operations & Supply Chain for Actinium Pharmaceuticals, Inc. and the Global Vice President and General Manager, Life Sciences & Specialty Chemicals for Honeywell International. Early in her career Cynthia spent more than 18 years at Pfizer in a variety of increasingly responsible leadership roles across multiple functional areas. She also served on the Drexel University Solutions Advisory Board, as a Board Director for Spark Therapeutics UK Ltd. and Spark Therapeutics Ireland Ltd. and is a member of Tome Bioscience's scientific and technical advisory board.